Articles tagged with Human Immunodeficiency Virus
A UBC-BC CfE study found that increased HAART coverage significantly prevents HIV transmission and reduces new diagnoses in British Columbia. The expansion of HAART treatment plays a crucial role in maximizing public health resources.
The new guidelines recommend initiating antiretroviral treatment (ART) as soon as possible for asymptomatic individuals with low CD4+ cell counts, and treating symptomatic patients regardless of their CD4+ count. The treatment should be individualized based on concurrent conditions and previous drug exposure.
A study found that only 51% of HIV-exposed infants in African countries received a minimum dose of nevirapine to reduce the risk of mother-to-child transmission. The study highlights the need for improved service coverage and counseling services to maximize prevention efforts.
A Canadian study found that the introduction of highly active antiretroviral therapy (HAART) for HIV patients in 1996 led to a significant decrease in new HIV diagnoses. The study showed that every 100 patients on HAART resulted in a 3% reduction in new HIV diagnoses.
A study found that routine HIV screenings in emergency departments resulted in a small increase in newly diagnosed HIV patients, with most diagnoses occurring late in the course of disease. The findings suggest that nontargeted opt-out rapid HIV screening may be an effective prevention strategy.
A recent NIH-supported study found that increasing HAART coverage in British Columbia reduced viral load and new HIV diagnoses among individuals with a history of injection drug use. The study's findings support the importance of maximizing HAART coverage within current medical guidelines to curb the spread of HIV.
The International AIDS Society (IAS) has announced the winners of four prestigious scientific awards, recognizing innovative HIV and AIDS research. The Women, Girls and HIV Investigator Prize was awarded to Naina Rani for her work on mainstreaming the Prevention of Parent to Child Transmission program in India.
Penn State researchers discovered that retroviruses like HIV take a detour through the cell nucleus before assembling new virus particles. Understanding this process could enable the development of drugs to stop the spread of infection.
Researchers developed two new risk models to predict the survival of HIV patients in sub-Saharan Africa. The models identified key factors such as CD4 cell count, clinical stage, and bodyweight that increase the risk of death. These predictions will aid in clinical decision making and improve treatment outcomes.
A new study found that HIV may increase the risk of death in people with high CD4 counts, but only moderately. The risk was highest among injecting drug users and heterosexual individuals, likely due to socioeconomic factors rather than HIV itself.
The International AIDS Society has awarded $3.4 million in grants to 10 early-stage researchers from diverse scientific disciplines, aiming to advance HIV understanding and prevention approaches. The grantees will collaborate with CFAR institutions to explore pressing scientific questions on long-term survival and HIV transmission.
A new review of existing literature found that several factors influence willingness to receive an HIV vaccine, including misconceptions about vaccine efficacy and fear of side effects. To ensure a future HIV vaccine is acceptable, public education is crucial to address these concerns.
The report identifies key gaps in current knowledge and proposes a multi-disciplinary research approach to support HIV-positive women's reproductive health. The recommendations aim to enhance their ability to achieve their desired family size and promote healthy services.
A study of gay male couples found that sexual agreements mainly improve relationship satisfaction and build trust. However, broken agreements can increase HIV risk when partners have different understandings of their agreement.
Three former Latin American presidents have signed the Vienna Declaration, calling for the incorporation of scientific evidence into illicit drug policies. The declaration aims to improve community health and safety by reducing consumption and harm caused by drugs.
A new study found that a culturally specific intervention program based on the African concept of Eban increased condom use and reduced acts of unprotected sex among heterosexual African American couples with differing HIV status. The program aimed to improve communication, relationship health, and community respect.
A couple-focused intervention appears effective in reducing HIV risk behaviors among African-American couples, particularly those with one partner HIV-positive. The study found that couples who participated in the Eban intervention reported more consistent condom use and fewer unprotected intercourse acts.
The International AIDS Society and National Institute on Drug Abuse have awarded fellowships to seven young researchers from around the world to study the intersection of drug use and HIV. The recipients will receive US$75,000 each to pursue groundbreaking research in biology, epidemiology, public health, behavioral sciences, and more.
Experts warn that failure to meet universal access pledge and budget cuts to prevention and treatment programs will deliver a major setback. Many African countries face depleting stocks of antiretroviral medications and reduced treatment coverage goals, increasing the risk of HIV drug resistance.
Researchers have found two human antibodies, VRC01 and VRC02, that can neutralize over 90% of known HIV strains. These antibodies could be used to design improved HIV vaccines or developed as a therapy for HIV infection. The discovery was made using a novel molecular device that targets specific cells making antibodies against HIV.
Increasing HAART treatment for people with HIV/AIDS lowers viral load, stops HIV progression, and prevents transmission. A comprehensive economic analysis shows expanding HAART coverage in British Columbia can deliver a net benefit of $900 million over 30 years.
A recent study published in PLoS Pathogens has identified two molecules, PPARγ and LXR, that can inhibit specific aspects of HIV transmission. The findings suggest that these molecules may be targets for therapies targeting mucosal HIV transmission.
A recent study found that the original HIV strain still exists in the body months after initial infection, with immune cells degrading it at an accelerated rate. The research analyzed over 100,000 genetic snippets and revealed that the virus mutates rapidly to evade the immune system, but certain portions remain persistent.
The Vienna Declaration urges governments and international organizations to adopt evidence-based approaches to illicit drug policy, recognizing addiction as a medical condition. This declaration aims to reduce harms deriving from current policies and redirect resources towards prevention, treatment, and harm reduction interventions.
A new report confirms that routine, jail-based HIV testing can identify a substantial proportion of people unknowingly infected with HIV. The study found nearly 170 new HIV diagnoses among Rhode Island inmates during an eight-year period, highlighting the potential for this testing to prevent disease spread.
Researchers at NPL have confirmed a definitive structure of an HIV protein, shedding light on its infection mechanism. This discovery may lead to better treatments for people affected by HIV.
In a groundbreaking study, researchers found that antiretroviral drug combinations given to pregnant and breastfeeding women in Botswana prevented 99% of the mothers from transmitting HIV to their infants. The study's findings have significant implications for maternal health and child survival in developing nations.
A randomized trial found that trained nurses can safely and effectively manage antiretroviral treatment, similar to doctor-monitored care. The study adds evidence to the success of 'task-shifting' in HIV care, which could help ease healthcare worker shortages and expand access to ART for millions in need.
Researchers found that adding nucleic acid testing to HIV screening can detect the presence of HIV earlier, increasing detection yield by 23%. A large majority of study participants received negative test results via automated phone or internet systems. The findings suggest that such programs can help control the HIV epidemic.
Alzheimer's disease may not be delayed by lifestyle interventions, while a promising medication, diet, exercise, and cognitive engagement show potential benefits. Ribavirin shows promise in treating Chronic Hepatitis E, and adding nucleic acid testing to HIV screening improves case yield.
Researchers found that mortality rates were significantly lower among patients who received DOT from a nominated treatment supporter compared to self-monitored ART. The study suggests that social capital and emotional support provided by these supporters contributed to improved survival outcomes.
The study reveals how HIV protein Tat interacts with the human protein P-TEFb, altering its shape. This knowledge may lead to the design of inhibitors that target P-TEFb only when it is interacting with Tat, potentially reducing viral replication without harming normal cell function.
The study found that 40-60% of Americans living with HIV/AIDS are smokers, twice the rate in the general population. Researchers emphasize the need for effective interventions to help these individuals quit smoking.
A RAND Corporation study finds that faith-based organizations in Central America can play a crucial role in the HIV response by raising awareness and providing access to healthcare. Researchers recommend building on these groups' existing reach and influence to improve services and support for those affected by the disease.
Researchers at Scripps Research Institute have determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus (HIV). The study advances the effort to develop an AIDS vaccine by providing insights into how broadly neutralizing antibodies work.
A study of nearly 45,000 patients found that many with HIV in the US and Canada do not receive care early enough, resulting in lower CD4 cell counts. This delay increases the risk of clinical disease progression and ongoing transmission.
A large multinational study found that antiretroviral therapy (ART) significantly reduces HIV transmission risk, with 349 HIV-infected partners initiating ART at a rate of 90% HIV transmission reduction. Regular CD4 measurements and counseling services were provided to all couples.
Research suggests that using lubricants during receptive anal intercourse can increase the risk of rectal sexually transmitted infections (STIs), including HIV. A study involving nearly 900 men and women found that those who used lubricants were three times more likely to have a rectal STI.
New research from the Microbicide Trials Network indicates that some lubricants have toxic effects on cells and rectal tissue. The study's findings support IRMA's calls for safer lubricant options, emphasizing the importance of condom use with compatible lubricants to prevent HIV transmission.
Researchers found that children born to HIV-positive mothers with specific TLR9 gene variants are at a higher risk of acquiring the virus. The study confirms the relevance of innate immunity in perinatal HIV-1 infection and may lead to new therapeutic strategies.
Researchers have developed vaginal rings that can deliver therapeutic levels of two anti-HIV drugs for up to 30 days, while quick-dissolve films and almond-shaped tablets also show potential. These new formulations offer an alternative to daily microbicide gels and could provide a safer and more effective way to prevent HIV transmission.
Researchers tested a vaginal microbicide gel containing an integrase inhibitor and found it provided significant protection against infection with a virus similar to HIV. The study showed promise for further evaluation of integrase inhibitors as a potential method for preventing HIV transmission in uninfected individuals.
New scientific advances offer significant promise for reducing the spread of HIV/AIDS and tuberculosis, including novel TB drugs, rapid diagnostic tests and bold prevention approaches like PrEP. Experts call for policymakers to capitalize on these advances to save millions of lives from these deadly epidemics.
Implementing the 3Is policy (Intensified tuberculosis case finding, Infection control, and Isoniazid preventive therapy) combined with earlier start of ART can prevent HIV-associated TB. Early diagnosis and treatment, along with a comprehensive package of HIV care, form the basis of prevention and control of HIV-associated TB.
The global burden of tuberculosis remains significant, with 11 million active cases in 2008, despite progress made since the start of DOTS era. Rapid expansion of TB diagnosis and treatment has saved up to six million lives, but further efforts are needed to eliminate the disease by 2050.
Researchers found that vaccinia immunization reduces HIV replication, suggesting it could provide protection against subsequent infection. The decline of smallpox vaccination in the mid-20th century may have led to a loss of this protection, contributing to HIV's rapid contemporary spread.
A recent study found that frequent alcohol consumption is associated with a faster decline in CD4+ cell counts in individuals with HIV disease. The research, conducted over 30 months, suggests that alcohol has a direct impact on CD4 cells and accelerates immune system decline.
Researchers have discovered that individuals with a specific HLA B57 gene carry more potent killer T cells, which can recognize and attack HIV-infected cells. This finding may lead to the development of vaccines that provoke a similar response in people without the gene.
A prescription drug, imiquimod, has been found to boost the effectiveness of future vaccines for bacterial and viral diseases like HIV and hepatitis C. Scientists have coated imiquimod with dextran-based microparticles, significantly increasing the efficiency of cellular uptake by immune cells.
The International Treatment Preparedness Group's new report documents early warning signs of devastating impact from global pullback on AIDS commitment and funding. People living with HIV often struggle to afford medicines for opportunistic infections, transport costs, food, and second-line medications.
LA BioMed is participating in the international IPM020 study of a dapivirine-containing microbicide gel to evaluate its safety and absorption. The study aims to reduce HIV transmission among women, with the goal of reducing the cycle of infection that has led to millions of deaths worldwide.
New research identifies the source of 'noise' in HIV gene expression, finding that transcriptional bursting generates exceptionally high levels of noise. This finding suggests that latency may be fundamental to the HIV life cycle.
The latest data on maternal mortality show significant progress in reducing deaths in countries like China, Egypt, Ecuador, and Bolivia. However, unexpected increases were found in the US, Canada, and Denmark. The analysis revealed that the number of women dying from pregnancy-related causes has dropped by over 35% globally since 1980.
The global maternal mortality ratio declined from 422 in 1980 to 320 in 1990 and 251 in 2008, with developing countries making significant progress. The study found that HIV accounts for nearly one out of every five maternal deaths, with six countries accounting for more than half of all maternal deaths.
A new study found that community-based organizations can effectively implement an evidence-based HIV/STD risk-reduction intervention with adolescents. The intervention increased condom-protected intercourse without reducing the frequency of sexual activity.
Researchers at Duke University Medical Center have discovered a set of naturally occurring antibodies that can block HIV's entry into certain blood cells. These polyreactive anti-phospholipid antibodies show promise as a potential new strategy for HIV vaccine design.
Researchers at Duke University found that Peregrine's PS-targeting antibodies can block the CCR5 receptor, a key portal for HIV to gain entry into blood cells. The study showed potent ability to induce specific effects that impact viruses, inducing β-chemokines to block HIV entry.
Researchers have uncovered the three-dimensional structure of a key protein found on the surface of a specific HIV-1 subgroup, providing valuable insights for vaccine design. The discovery reveals unusual autoreactivity between an anti-HIV antibody and the CD4 receptor, raising questions about potential autoimmune responses.
A novel stem cell therapy has been developed to arm the immune system against HIV, potentially improving quality of life and life expectancy for those who have failed antiviral drugs. The therapy involves delivering antiviral DNA to patient immune cells, which can block viral gene production using RNA interference.
A study analyzed factors associated with HBsAg loss in HIV-HBV co-infected patients. Higher baseline CD4 cell counts were linked to increased loss of HBsAg, suggesting effective T-cell response against HBV. The research contributes to understanding predictors of HBsAg loss and its implications for management.